Gland Pharma: Appointment of Chief Executive Officer for Gland Pharma International Pte
Gland Pharma (GLAND) filed a disclosure titled "Appointment of Chief Executive Officer for Gland Pharma International Pte". The company is valued at about ₹51,070 crore.
What happened
Gland Pharma (GLAND) filed a disclosure with the exchanges on 30 October 2026 at 04:34 PM titled "Appointment of Chief Executive Officer for Gland Pharma International Pte".
From the filing: "Gland Pharma Limited has informed the Exchange about the Appointment of Chief Executive Officer for Gland Pharma International Pte."
Company snapshot
Gland Pharma is a mid-cap company in the Healthcare sector, with a market value of about ₹51,070 crore.
The stock last traded at ₹3,095.9, against a 52-week range of ₹1,573.6–₹3,171 (2.4% below the high).
Before this filing the shares had moved +6.2% over the month and +22.1% over three months. Average daily turnover over the last 20 sessions was about ₹121 crore.
Promoters held 51.77% at the end of Q1 FY27, down 0.06% points from the previous quarter. Foreign institutions owned 8.74% and domestic institutions 30.44%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,506 | 215.5 | 13.08 |
| Q2 FY26 | 1,487 | 183.7 | 11.15 |
| Q3 FY26 | 1,695 | 261.5 | 15.87 |
| Q4 FY26 | 1,743 | 366.7 | 22.26 |
| Q1 FY27 | 1,800 | 317 | 19.23 |
What history shows
BCEIE's records show 8 previous management change filings from the company since May 2026.
After those filings, the stock gained 0.1% on average the next trading day and was up 0.4% on average after five days (5 filings with price data).
Across 106 similar disclosures by other Healthcare companies, shares moved +1.0% on average the next day and +1.7% over five days; 50% of them rose the next day.
Market-wide, 4,059 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 44% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 1 Oct 2026 | Resignation of Mr. Wenjie Zhang as a Non-Executive & Non-Independent… | +4.6% | — |
| 14 Aug 2026 | Management change | −1.9% | −5.0% |
| 20 Jul 2026 | Change in Director(s) of the company. | −0.8% | −1.3% |
What to watch
- The appointment of a successor and any change in strategy or guidance.
- 6 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- U.S. FDA issues four observations to Gland Pharma formulation facility near Hyderabad
- Neuland Expands Sterile API Capacity with Gland Pharma
- Gland Pharma Ltd. Estimates – NSE:GLAND
- Did Gland Pharma's 77% Run Pass You By? What Bulls Still Need
- Gland Pharma sets November 9 vote: what it means for Gland Pharma stock
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.